Argenx Se (ARGX) Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Assets came in at $10.0 billion in Q2 2026, up 39.81% on a YoY basis from $7.2 billion in Q2 2025, and up 15.54% quarter-over-quarter from $8.7 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Assets for 12 consecutive years, with $10.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets rose 39.81% year-over-year to $10.0 billion; the trailing twelve-month figure through Jun 2026 stood at $10.0 billion (up 39.81% YoY), and the FY2025 full-year result was $8.7 billion, up 39.99% from the prior year.
- Assets improved to $10.0 billion in Q2 2026 per ARGX's latest filing, from $8.7 billion in the prior quarter.
- Across five years, Assets topped out at $10.0 billion in Q2 2026 and bottomed at $3.1 billion in Q4 2022.
- Historically, Assets has averaged $5.7 billion across 5 years, with a median of $4.8 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Assets slipped 1.71% in 2023, then soared 50.18% in 2024.
- Over 5 years, Assets stood at $3.1 billion in 2022, then jumped by 44.93% to $4.5 billion in 2023, then surged by 36.55% to $6.2 billion in 2024, then jumped by 39.99% to $8.7 billion in 2025, then advanced by 15.54% to $10.0 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $10.0 billion, $8.7 billion, and $7.2 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 2.10 Bn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 23.65 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.03 Bn |
| Dec 31, 2025 | 8.68 Bn |
| Jun 30, 2025 | 7.18 Bn |
| Dec 31, 2024 | 6.20 Bn |
| Jun 30, 2024 | 4.80 Bn |
| Dec 31, 2023 | 4.54 Bn |
| Jun 30, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.25 Bn |
| Dec 31, 2021 | 2.85 Bn |
| Jun 30, 2021 | 3.21 Bn |
| Dec 31, 2020 | 2.21 Bn |
| Jun 30, 2020 | 2.23 Bn |
| Dec 31, 2019 | 1.59 Bn |
| Jun 30, 2019 | 1.13 Bn |
| Dec 31, 2018 | 660.25 Mn |
| Jun 30, 2018 | 429.66 Mn |
| Dec 31, 2017 | 436.72 Mn |
| Jun 30, 2017 | 203.95 Mn |
| Dec 31, 2016 | 114.20 Mn |